by Raynovich Rod | Apr 26, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-2 4/29 12:15p Mid-day trading -Healthcare weak as Investors rebalance to other sectors. Gilead Sciences (GILD) up over 6% and. boosts overall market with positive remdesivir data. NAZ up 2.84%, IBB up 1.3%, IJR break-out? Technology, financials and energy show...
by Raynovich Rod | Apr 4, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools
Coronavirus (COVID-19) is an infectious disease currently spreading across the globe. Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness and recover. Others (particularly elderly people and those with underlying medical...
by Raynovich Rod | Mar 8, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
3/30 11;30a Major news on COVID-19 diagnostics spark rally. Abbott launches 5 minute test. ABT up 7.28% ,JNJ up 6.8%, all large caps up, IBB up 2.55, XBI up 1.61%. Risk reward still looks good for biotech by year-end 2020. See IBB 2 yr chart below. ======== 3/27 After...
by Raynovich Rod | Aug 19, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Update -3 Bearish trends in biopharma continue with both the IBB and XBI down with 30 min of trading to go. We will do a review of the healthcare sector later this week continuing the theme after the AACC of the need for diversification within healthcare e.g. medtech,...
by Raynovich Rod | Apr 21, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-3 XLV up from bottom at $86 to $88.63. IBB holding but more choppy at $107 level. Update-2 12p EDT-IBB flattish at $106 as earnings on large caps come in-will be reviewed at end of week. ABBV down 0.8% on Humira concerns:, profit forecast raised EPS gains...
by Raynovich Rod | Apr 15, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-2 10:45a 4/17…XBI down 3.37% to FEB support at $86. Healthcare issues are spilling over to biotech.Red screen day and all biotechs hit very hard.Drug pricing models are under scrutiny. Update-1…NASDAQ ekes out small gains but large cap biotechs...
by Raynovich Rod | Mar 29, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-4. 4/3 11:45A… Mid and Small Cap biotechs are momentum leaders: XBI hits 2019 high at $92.50. Update-3 4/2/19… Biotechs Outperform Major Market Indices Gene therapy stocks rally big: SGMO 28.96%, VYGR 7.38%, CRSP 6.91% NTLA 4.9% MGTX up 4.6%,...
by Raynovich Rod | Feb 25, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update: 1:40 EST 2/25… Gene Therapy stocks soar on Spark (ONCE) Deal: BLUE, CRSP, RARE; and XBI up 4.2%. Another big deal as GE sells healthcare business to Danher (DHR) for $21.4B; GE up 8.26%, DHR up 8.38%. ========== M&A Drives Mid and Small Cap Biotechs...
by Raynovich Rod | Feb 14, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update: GenMark (GNMK) Soars on Q4 and Full Year 2018 Results Revenues of $70.8M were 35% over 2017 Results Q4 Revenues were $19.4M an increase of 21% over prior year. ePlex Revenues for Q4 were 412.1M an increase of 110% over prior year. Loss per share was reduced...
by Raynovich Rod | Jan 24, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update ….Jan 30 2:45p EST …FED to be Patient and Policy Stance is Appropriate FED to “wait and see” before raising rates-stocks soar. FED-“US Economy in a good place” NASDAQ up 2%, DOW up 1.73%, S&P up 1.53% XLV up 1.27%, IBB...